S8 Ep7: Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer

Targeted Talks · Oct 6, 2026 · 11m

Komal Jhaveri, MD, joins Targeted Talks to discuss the FDA approval of imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) for patients with ESR1-mutated, estrogen receptor–positive, HER2-negative metastatic breast cancer. She explains the unmet need, noting that existing endocrine monotherapies leave many patients without a durable benefit. She then reviews the design of the phase 3 EMBER-3 trial (n = 874) and the updated analysis with 28.5 months of follow-up. In ESR1-mutated disease, progression-free survival with imlunestrant monotherapy was 5.5 vs 3.8 months (HR, 0.62)…